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The Pharmacology of Hemoglobin Switching: Of Mice and Men 
By Timothy J. Ley 
OW DO RED BLOOD CELLS (RBCs) switch from  H fetal to adult-type  hemoglobin (Hb)  production at 
the time of birth? The structures of  fetal and adult Hbs and 
the genes that encode them  have been  known for many 
years,  but  this  knowledge  has  not  readily  yielded  the 
molecular mechanisms underlying the switch. The mysteri- 
ous switch is a transcriptional one: the fetal (y) globin genes 
are actively transcribed in fetal RBCs, but in adult RBCs, 
the P-globin genes are transcribed at a much higher rate 
than the y-genes.’ 
Since  the  discovery  of  fetal  Hbs,  investigators  have 
proposed  that  reactivation  of  fetal  Hb  (HbF)  synthesis 
would  lessen the severity of  diseases caused  by  P-globin 
gene mutations.  These hopes were further strengthened 
when normal individuals with large amounts of circulating 
HbF  were identified; these people have “Hereditary Persis- 
tance of  Fetal  Hemoglobin”  and no medical problems.’ 
Preventing  or  reversing  the  switch  from  normal  HbF 
synthesis to defective adult Hb  synthesis could, therefore, 
be a therapeutic  goal, because high HbF  levels do not cause 
problems in otherwise normal individuals. But how could 
this goal be achieved? Remarkable studies over the past 
decade have taken us closer to an answer. 
THE  METHYLATION  HYPOTHESIS 
Shortly after the human P-like globin genes were cloned 
and sequenced, van der Ploeg and Flavell correlated the 
methylation status of DNA sequences near the globin genes 
and the activities of  these genes in different tissues.’ The 
human  y-globin  genes were  undermethylated  in  tissues 
where they were normally expressed (like fetal liver), but 
were  heavily  methylated  in  adult  erythroid  cells  or  in 
non-erythroid  tissues. This observation led to the forma- 
tion of  a simple hypothesis: if  one could cause DNA near 
the y-globin genes of  adult bone marrow cells to become 
hypomethylated,  these genes might resume  transcription 
and HbF production would increase. Joe DeSimone  and 
Paul Heller seized upon this idea and decided to test it in a 
primate model of  Hb switching that they had developed. 
They knew that the basic structures of  the fetal and adult 
globin genes of  baboons  and humans were  similar, and 
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proposed that the methylation hypothesis could be directly 
tested in this model. 
In the late 1970s and early 1980s, a number of  investiga- 
tors had shown that the drug 5-azacytidine could block the 
activity  of  the  enzyme  that  normally  methylates  newly 
synthesized DNA, causing the DNA in  dividing cells to 
become hypomethylated? Treatment of  tissue culture cells 
with this drug sometimes activated  specific genes and/or 
specific developmental “programs.” Throughout the 1970s, 
5-azacytidine  had  also  been  tested  in  phase  I  trials  of 
patients with acute non-lymphocytic  leukemia. The pharma- 
cology and toxicities of  5-azacytidine were, therefore, well 
understood in 1981, when this drug was first administered 
to baboons. In the first experiments with the drug, 5-azacy- 
tidine caused tremendous elevations of  HbF levels in the 
phlebotimized  baboon^.^ The  precise mechanism of y-globin 
gene activation could not be rapidly determined in baboons, 
because the structures of  all the globin genes was not yet 
known. 
In collaboration with DeSimone and Heller, Art Nien- 
huis and I used the information from the baboon trials to 
design treatment protocols for human patients with severe 
sickle cell anemia or p-thalassemia; George Dover and Sam 
Charache  independently  treated  a  group  of  sickle  cell 
patients at Johns Hopkins at the same time. To our delight, 
relatively  non-toxic  doses  of  5-azacytidine  dramatically 
increased HbF synthesis in almost all of the individuals who 
were tested?.’ The drug indeed caused hypomethylation of 
the newly synthesized DNA found in bone marrow cells.5s6 
Despite evidence for widespread  DNA hypomethylation, 
only a restricted cohort of  genes (including the y-globin 
genes) seemed to be  activated  by  the treatment.’  These 
results  suggested  that  either  the  y-globin  genes  were 
somehow primed to be reactivated  in adult bone marrow 
cells, or that other mechanisms were partially responsible 
for the augmented HbF  synthesis. 
THE ”ERYTHROID  REGENERATION”  HYPOTHESIS 
Observations made in the 1970s by Alter et aI8 suggested 
that erythroid regeneration was associated with an altered 
“program” of  HbF synthesis in  erythroid progenitor  and 
precursor cells. Because 5-azacytidine is a cytotoxic com- 
pound,  Nathan,  Stamatoyannopoulos,  Papayannopoulou, 
and their colleagues argued that cytotoxicity and erythroid 
regeneration  may  have  caused  5-azacytidine’s effects on 
HbF  production:  and  suggested that alternate cytotoxic 
drugs  (that  did  not  directly  inhibit  DNA  methylation) 
would  have  the  same  effects.  Indeed, hydroxyurea  and 
AraC were  both  shown to increase  HbF production  in 
primates  and  in  humans.’””  “Demethylation”  of  newly 
synthesized DNA was, therefore, not necessary to augment 
HbF  production. However, in the final analysis, azacytidine 
still seems to work  by  both  mechanisms: first, it  causes 
newly synthesized bone marrow DNA to become hypometh- 
ylated; and, secondly, it is cytotoxi~.’~~’~ 
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These early  experiments with  pharmacologic  “reverse 
switching” demonstrated that the switch was “plastic” and 
could be manipulated. However, all of  the drugs used to 
manipulate the switch were cytotoxic, anti-leukemia drugs 
with uncertain potentials for causing secondary malignan- 
cies if  administered over long periods of  time. Of the three 
drugs tested, hydroxyurea had the least clearcut potential 
for causing harm, and already had a proven safety record in 
patients with myeloproliferative diseases. For this reason, 
clinical  trials  with  hydroxyurea  have  been  initiated  in 
patients with sickle cell anemia,17s18  and a phase I11 trial is 
currently being considered to test its ability to reduce crisis 
frequency. Nonetheless, long term administration of  cyto- 
toxic compounds will never be an ideal therapeutic option 
for patients with hemoglobinopathies. The ideal pharmaco- 
logic compound would obviously have little or no toxicity 
and would be safe to administer to children during periods 
of  normal growth and development. The search for such a 
compound has continued to demonstrate the usefulness of 
large animal models to identify drugs that can alter patterns 
of globin synthesis in humans. 
Ginder et all9  first demonstrated that embryonic chicken 
globin genes could be reactivated by administering 5-azacy- 
tidine  and butyrate  compounds to adult  chickens.  Both 
drugs were required for the effect, and a “two-hit’’ model 
for embryonic globin gene reactivation  was proposed. In 
subsequent years, Perrine et alm  and Bard and Prosmanne” 
demonstrated that butyrate metabolites were persistently 
elevated in the infants of  diabetic mothers, who undergo 
delayed  HbF switching after birth.  Butyrate  compounds 
were subsequently shown to delay the fetal to adult globin 
switch in developing sheep;’  and to augment HbF produc- 
tion in baboons.= Butyrate compounds have not yet been 
tested in humans, because safety issues have not yet been 
addressed. 
Hematopoietic growth factors can also alter patterns of 
Hb  synthesis.  Because  erythropoietin  administration  is 
known to cause a form of  erythropoietic “stress,” Al-khatti 
et alZ4  tested this drug in baboons and detected augmenta- 
tion  of  fetal  globin  synthesis.  However,  the  effect  of 
erythropoietin on HbF  production in sickle cell patients has 
been minimal thus far.”  Finally, granulocyte-macrophage 
colony-stimulating  factor (GM-CSF) augments HbF produc- 
tion in cultured erythroid progenitors?  but its effects on 
HbF have not yet been tested in animal models. 
Although almost all of the work regarding pharmacologic 
manipulation of  HbF has been  developed  in primate or 
large animal models, these models remain extremely cum- 
bersome and expensive to use. They are not well suited for 
surveys of compounds, and because of  differences between 
the globin gene clusters of higher primates and humans, not 
all of the results can be directly extrapolated to humans. A 
better animal  model  for testing pharmacologic  agents  is 
clearly required; in this issue of Blood, Constantoulakis et 
aIz6  describe a transgenic mouse model that fulfills many of 
these  requirements.  To  understand this  model,  a  brief 
review of  human globin gene regulation in transgenic mice 
is useful. 
DEVELOPMENT AND TISSUE-SPECIFIC EXPRESSION OF 
HUMAN GLOBIN GENES IN TRANSGENIC MICE 
Early attempts to study the expression of  human globin 
genes in  transgenic  mice  were  at times  frustrating, but 
ultimately,  these studies  proved  to be  very  informative. 
When an entire human P-globin gene was integrated into 
the germline of  transgenic mice, only a small proportion of 
the founder animals expressed the $-globin gene27*28;  usu- 
ally, the P-globin transgene was expressed at much lower 
levels than the endogenous mouse $-major globin genes. 
Even so, human $-globin gene sequences targeted expres- 
sion exclusively to adult erythroid tissues; that is, the DNA 
sequences required for expression in RBCs at the correct 
stage  of  development  were  present  within  or near  the 
P-globin gene.27,28  Experiments performed by three separate 
groups,  including  Kollias  et  al,29  Behringer  et  al,M and 
Trudel et a1,3’  demonstrated  that the sequences required 
for adult erythroid-specific expression were located within 
and immediately 3’ to the P-globin gene. 
When human y-globin genes were tested in transgenic 
mice,  a  different pattern  of  expression  emerged.  When 
these studies were performed, there was only one recog- 
nized murine Hb switch from the embryonic stage (yolk 
sac) to the adult stage (fetal liver and adult bone marrow). 
Mice were thought to have embryonic $-like globin genes 
and adult  P-globin genes, but nothing  corresponding ex- 
actly to the y-globin genes of  humans. More recent studies 
suggest that there may  in fact be embryonic-to-fetal and 
fetal-to-adult switches in the mouse”; regardless, the devel- 
opmental fate of  y-globin transgenes was difficult to pre- 
dict. To the surprise of  most workers in the field, human 
y-globin transgenes were  expressed  only at the yolk  sac 
(embryonic)  stage  of  de~elopment!~~.”  This finding sug- 
gested that the embryonic stage is more akin to the fetal 
stage of  erythroid development in humans, and suggested 
that  “fetal”  stage-specific  factors  were  present  in  the 
embryonic RBCs of  developing mice. In contrast  to the 
human  p-globin  gene,  y-globin  sequences  required  for 
targeting to embryonic RBCs are located upstream from 
the  y-gene~?’.”’~ However,  transgenic  mice  containing 
y-globin transgenes behaved similarly to the P-globin trans- 
genics in two regards: first, only a small proportion of  the 
transgenic mice  expressed  the y-globin transgenes,  and, 
secondly, the level of  expression was much lower than that 
of  the embryonic mouse globin  gene^."*'^-^^ Certainly all of 
the early transgenic studies suggested that sequences within 
or near  the  y-  or  P-globin  genes were  responsible  for 
targeting the expression of  these genes to the appropriate 
tissue at the appropriate developmental stage. These exper- 
iments  also  suggested  that  additional  DNA  sequences 
would be required for high level expression of human globin 
genes in the erythroid cells of most transgenic mice. 
THE LOCUS CONTROL REGION (LCR) OF THE P-GLOBIN 
GENECLUSTER 
The first clues regarding the nature of  these sequences 
came from the studies of  Tuan et a136  and Forrester et al?’ 
who discovered a series of  six DNAse I hypersensitive sites 
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located far upstream and far downstream from the human 
p-like globin  gene cluster  (see Fig  1). These DNAse  I 
hypersensitive sites were erythroid-specific but developmen- 
tally stable; that is, these regions of chromatin were “open” 
and  DNAse  I  hypersensitive  at  all  stages  of  erythroid 
development. Forrester et aI3*  went on to show that these 
DNAse I hypersensitive sites were reconstituted when  a 
non-erythroid human chromosome 11 was transferred into 
the mouse  erythroleukemia cell environment,  suggesting 
that the locus itself contains all of the information required 
to form an active chromatin domain. They wined the term 
“locus activation region” (LAR)  to describe this function. 
More recently, Dhar et a139  have shown that several of these 
sites  are hypersensitive  in  non-erythroid  and even  non- 
hematopoietic cell lines; only 5’ HS-3 (see Fig 1) is DNAse 
I hypersensitive only in erythroid cell lines. 
At  about  the  same  time,  Grosveld  et  a1  decided  to 
determine whether  DNA  sequences  derived  from  this 
upstream region contained the “missing” information nec- 
essary for high level expression of  human globin genes in 
transgenic mice. To their surprise, every transgenic founder 
line containing a 6-globin gene linked with the far upstream 
region expressed its transgene at a level that was similar to 
that of the endogenous mouse p-major genes.39  The number 
of copies of the transgene in the mouse genome was directly 
correlated with the level of  transgene expression. Further- 
more,  expression of  the transgenes did  not  seem  to be 
dependent on the position  of  transgene integration. The 
function of the p-globin transgenes was therefore said to be 
“position  independent” and  “copy-number  dependent.” 
Because  of  the powerful effects of  the upstream region, 
Grosveld  called  these  sequences  the  dominant  cmtrol 
region (DCR). (Conferees at the 7th Conference on Hemo- 
globin Switching agreed upon the consensus name “Locus 
Control Region” [LCR] for this region, and further agreed 
that the individual DNAse I hypersensitive sites [HS] would 
be named 5‘ HS-1,2,3,4,  and 5 upstream from the €-globin 
gene, and 3’ HS-1 downstream from the p-globin gene, as 
indicated in Fig 1). 
Because of  the powerful and interesting activities of  the 
LCR in transgenic mice, a number of  laboratories rapidly 
confirmed and extended these early res~lfs.”~~~~  The LCR 
was shown to activate a-globin gene expression in trans- 
genic mice,”.”  suggesting that the a-globin locus on chromo- 
some  16  might  also  be  under  the  influence  of  similar 
sequences  (see  below).  Co-injection  of  ci-  and  p-globin 
5’HS:5  4  3  2  I 
-21.4  -16-14.7 -10.9  -6.1 
genes with  the LCR  has resulted  in  mice making large 
quantities of  human Hb44345;  mice producing HbS  have been 
made  by  coinjecting  a- and  p‘-globin  genes  with  the 
LCR.46,47 
The importance of  the LCR for P-globin gene function in 
vivo has also been recently established. Driscoll et ala have 
identified a 30-kb deletion that removes 5‘ sites 2-5 in an 
Hispanic patient with ySp thalassemia (Fig 1). The entire 
p-globin cluster on this chromosome is intact, but none of 
the genes in the cluster are functional. Forrester et a149  have 
recently shown that this deletion closes the normally open 
chromatin “domain” of  the p-globin gene cluster in eryth- 
roid cells, and that it delays the replication  of  the p-like 
genes during the cell cycle. 
Because the region containing the LCR sequences spans 
a large stretch of  DNA, investigators immediately tried to 
identify the critical functional sequences within this region. 
Initial studies focused on the DNAse I hypersensitive sites 
themselves.  Accordingly,  DNA  sequences  between  the 
hypersensitive sites were removed in successive deletions 
creating “mini-LCR” and “micro-LCR”  which 
seemed to retain  all of  the detectable  LCR functions in 
studies performed with transgenic mice or mouse erythro- 
leukemia cells. DNA sequences near 5‘ HS-2 and -3 have 
most of the activity in these  but 5‘ HS-1 and -4 
also seem to have more subtle functions. The combination 
of  all four 5‘ sites is required apparently for full function of 
the LCR in transgenic mice.”1353 
How  does  the  LCR  normally  function  in  erythroid 
precursors? The answer to this question is not yet known, 
but intense investigations in a number of  laboratories have 
begun  to find  a  number  of  clues.  First, when  LCR  se- 
quences are integrated into genomic DNA, they seem to be 
able to open a chromatin domain and keep it open, isolating 
sequences within  the  domain  from  potentially  negative 
influences nearby. The LCR, therefore, seems to increase 
the  number  of  “productive  integration  events”;  hence, 
nearly every transgenic mouse containing a P-globin gene 
linked to an LCR expresses the transgene. Secondly, the 
LCR  seems  to have  classical enhancer  function  that  is 
relatively specific for erythroleukemia cells. Tuan et 
were the first to demonstrate this enhancer effect with 5’ 
HS-2; these results have been confirmed and extended by 
other groups within the past year.55s56  The LCR also seems 
to make  a  variety  of  globin  and  non-globin  promoters 
inducible  in  erythroleukemia cells;@59 suggesting that  at 
3’HS: I 
+21.8 
Hispanic Y&BThal, 
91  IO Kb 
Fig 1.  Map of the human p-globin gene cluster. The locations and names of the 5’ and 3’ HS are shown. The numbers above the arrows  refer to 
the distances (in kilobases)  of the 5’ sites upstream  from the €-globin  gene, or of the 3’  site downstream  from the p-globin gene. The 3’ breakpoint 
of the.Hispanlc ySp thalassemia is shown; this deletion  removes -30 kb of DNAfrom  this region.” 5‘ HS 1  through 4 are now called the LCR.” 
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least some of  this inducibility function lies within the LCR 
it~elf.5~  The precise molecular mechanisms that determine 
these effects are not yet understood in detail. However, Ney 
et al,55*60  Talbot et a1,61 and Moi and Kad6  have suggested 
that sequences near a directly repeated AP-l/NF-E2 site 
within 5‘ HS-2 are absolutely required for several of  the 
functions listed above, and that specific transcription fac- 
tors bind to these sites and influence the function of the 
LCR  sequences. A  region  with  different  primary  DNA 
motifs appears to be  responsible for the activity of  5‘ HS-367; 
perhaps different  transcription  factors may  regulate  the 
function of  this site. 
Additional proof of  the importance of 5’ HS-2 sequences 
has recently come from experiments that detected evolution- 
ary conservation of the critical regions in this site. Because 
mice have the ability to recognize human LCR sequences, 
Anne Moon and 163 reasoned  that mice might also have 
LCRs.  Indeed, 5’  HS-1 and -2 are highly conserved up- 
stream from the mouse P-globin cluster. The region within 
5’ HS-2 known to be important for the function of this site is 
absolutely  conserved  between  mice  and  humans,  even 
though  these  sequences  do  not  encode proteins.  This 
remarkable degree of  conservation is similarly preserved in 
the goat: Li et a1 have simultaneously demonstrated that 5‘ 
HS-1, -2, and -3 are all conserved in location and position 
upstream  from the goat  @-like  globin gene cluster.”  Re- 
ports of  evolutionary conservation of  LCR structure and 
function are beginning to emerge in other animal species as 
Finally, Higgs et aI@’ have now shown that the a-globin 
gene cluster also has a locus control region located some 30 
kb upstream from the t;-globin gene in a DNAse 1  hypersen- 
sitive site that contains several small motifs related to  those 
found  in  the  P-LCR.  The importance  of  this  upstream 
region for function of the a-globin gene cluster has been 
established in vivo. Hatton et a167  and Liebhaber et alS have 
described  deletions  that  remove  the a-LCR  region  but 
leave the a-globin genes intact. The a-like globin genes on 
both  of  the  chromosomes  bearing  these  deletions  are 
non-functional. 
we11.65 
HUMAN Hb SWITCHING IN TRANSGENIC MICE 
With the discovery of  the LCR, investigators in several 
laboratories  added  LCR  sequences  to  the  E-,  y-,  and 
P-globin genes, and repeated the earlier transgenic experi- 
ments  (see Table  1).  Surprisingly, the  LCR  seemed  to 
disrupt  the  “normal”  developmental  expression  of  the 
individual y- and @-globin  genes in transgenic mice. For 
example, while the y-globin gene alone is expressed only in 
embryonic RBCs, y-globin genes linked with the LCR are 
expressed  in  both  embryonic  and  adult  RBCS!~~.~’  The 
p-globin gene alone  is normally expressed  only in  adult 
RBCs;  the  @-globin gene  attached  to the  LCR  is  also 
expressed in both embryonic and adult RBCS.~’  In contrast, 
the human  €-globin gene is not  expressed in any mouse 
tissue when injected alone; €-globin  genes plus the LCR are 
expressed in embryonic but not adult RBCS.’~,” The €-globin 
gene is, therefore,  “autonomously” regulated in the pres- 
ence of  the LCR, but the  y- and p-genes are not. 
Table 1.  Developmental  Regulation of Human p-Like Globin Gene6 in 
Transgenic Mice 
Embryonic  Adult 
Globin  Erythroid  Erythroid 
Transgene  Expression  Expression  References 
€  -  - 
E + LCR  +  -  71.72 
Y  +  -  31,33-35 
-y  + LCR  +  +  69,70 
-  +  27-31  P 
p + LCR  +  +  40-42.70 
yiip + LCR  Y+#  B-  7-8  P+ 
yii-  + LCR  Y+  Y+  70,73 
Simplified summary of  human p-like globin gene activities in trans- 
genic mice. + and - symbols indicate the presence or  absence of 
transgene  activity  in the  indicated  erythroid tissues.  ”Embryonic“ 
erythroid cells are yolk-sac derived (day 9 to 10); ”adult“ erythroid cells 
may be derived from late gestational stage fetal livers (day 12 to 14). 
adult bone marrow, or adult reticulocytes. No attempt has been  made in 
this table to indicate  the relative activities of the transgenes. In general, 
constructions containing the LCR  are expressed at  high levels in all 
transgenic mice. Modified  with permi~sion?~ 
To address this quandary of  developmental disregulation 
with  the LCR,  Behringer  et a17’  and Enver  et aln  both 
decided to add the LCR to the intact ySp  region of  the 
p-globin cluster and repeat the experiments. Both groups 
demonstrated that appropriate y +  P switching did occur in 
this context. As  shown in Table 1, the y-globin gene was 
expressed at high levels in embryonic RBCs and the P-gene 
was not. In contrast, the y-gene was “silenced”  in adult 
erythroid tissues, and the P-gene was fully active. These 
experiments suggested a competitive model of  regulation 
for the y- and P-globin genes in transgenic mice; this model 
gained  further credibility in an additional experiment in 
which the P-globin gene was deleted from the large ySp 
fragment.m With this construction,  the y-gene was again 
inappropriately  expressed  in  adult  erythroid  tissues.  A 
model where  the y- and P-globin genes compete for an 
LCR function best explains these results, but more recent 
experiments from Fraser, Grosveld, and colleagues suggest 
that the y-globin gene can, in fact, be silenced  “auton- 
omously” in adult erythroid tissues if  additional 3’ y-globin 
gene flanking sequences and 3’ HS-1  are added to the 
transgenic   construction^.^^  Further  experiments  will  be 
required to sort out the precise DNA sequences that cause 
the  differences  between  these  models.  Nonetheless,  an 
accurate  recapitulation  of  human  y-  --*  P-globin  gene 
switching has now been accomplished in transgenic mice, 
opening the door for the testing of  pharmacologic agents in 
a mouse model. 
PHARMACOLOGIC MANIPULATION OF HUMAN Y-GLOBIN 
GENE ACTIVITY  IN TRANSGENIC MICE 
In this issue of Blood, Constantoulakis et aIz present data 
from  the first  small  animal  model  designed  to  test  the 
effects of  pharmacologic  agents known to augment HbF 
synthesis in humans.  Three different  kinds of  transgenic 
mice were  tested.  In the first, transgenic  mice with  the 
y-globin gene alone (expressed only in embryonic RBCs) 
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did not respond to any of  the pharmacologic agents known 
to increase human HbF  synthesis. In the second group of 
mice,  a  y-globin  gene was  linked  with  a  “micro-LCR” 
cassette.  This  y-globin  gene  is  now  “disregulated”  and 
expressed in embryonic and adult erythroid cells (see Table 
1). However, when adult mice from this founder line were 
treated with 5-azacytidine, hydroxyurea, butyrate, or eryth- 
ropoietin,  a  striking  increase  in  the  number  of  HbF- 
containing reticulocytes and in y-globin mRNA levels were 
observed. These results are specific for the y-globin gene, 
because a P-globin-LCR  mouse did not respond to these 
agents. These results seem  to indicate that the y-globin 
gene and the LCR sequences somehow interact with each 
other to produce this effect,52259  and suggest that all of  the 
DNA sequences required  for  a  response to these  drugs 
must lie within the “micro-LCR’ and/or the y-globin gene 
itself. The y-LCR model for pharmacologic manipulation is 
extremely powerful, but perhaps transgenic mice contain- 
ing the entire y80-globin gene cluster plus the LCR will be 
even  more  useful,  because  these  animals  have  a  more 
“physiologic” switching mechanism in play. Regardless, a 
small animal model that can detect the effects of  drugs on 
human  y-globin  gene activity  is  now  ready  for  further 
testing.  The availability of  such  a  model  should  greatly 
enhance our ability to identify pharmacologic agents for the 
treatment  of  patients  with  P-thalassemia  or  sickle  cell 
anemia. 
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